HYK华因康品牌怎么样 申请店铺

我要投票 HYK华因康在基因检测行业中的票数:254 更新时间:2025-05-18
HYK华因康是哪个国家的品牌?「HYK华因康」是 深圳华因康基因科技有限公司 旗下著名品牌。该品牌发源于广东,由创始人盛司在2008-01-23期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力HYK华因康品牌出海!将品牌入驻外推网,定制HYK华因康品牌推广信息,可以显著提高HYK华因康产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

HYK华因康怎么样

华因康集团秉承“专业、严谨、创新、服务”的理念,自2008年创立以来,一直致力于中华民族健康事业,发展迅猛。迄今拥有深圳市华因康高通量生物技术研究院、深圳华因康基因科技有限公司、华因康基因检测中心及全国各地多家分支机构,成为以基因技术为核心,拥有雄厚研发支撑、具备研发、生产和应用三位一体的完整产业链的生物技术高科技集团。

研发中心–深圳市华因康高通量生物技术研究院拥有一支在机械、光学、电子、生化、软件、生物信息、生物医疗等技术领域具备尖端技术成果的科学家、教授、博士、博士后及行业专家组成的精英技术团队。研究院面向世界科学前沿和国家战略发展需求,以新型DNA测序分析技术的突破为契机,旨在研究高通量生物技术,开发高通量实验和检测设备,寻找高通量检测新方法,为我国生命科技领域的上游进行产业布局,搭建与基因技术相关的生命科技产业基础性研究平台,进行国际前沿基因组科学基础及应用研究与技术开发,提升我国基因技术自主创新能力。

产品中心-深圳华因康基因科技有限公司专业生产、销售高通量基因测序设备、生物试剂和基因信息分析软件,提供科研技术服务与生物信息数据分析技术服务。公司主导产品PSTAR高通量基因测序系统,填补了我国在生命科技产业核心装备、基因测序设备制造、试剂生产与生物信息分析服务等领域的空白,广泛应用于生命科学基础研究、临床诊断与治疗、疾病预防与保健以及新药研制等领域。

基因检测中心-华因康基因检测中心依托于华因康基因新一代高通量基因测序系统平台技术,是转化医学的专业化服务机构。中心以新一代高通量基因测序系统技术平台为核心,辅以实时荧光PCR平台、STR分析平台、免疫组化、荧光原位杂交等技术平台,覆盖了DNA、RNA、蛋白水平,测序、PCR、蛋白免疫组化、FISH等多种检测技术。已率先研发出多种适用于亚洲人的临床基因检测项目,专业提供“肿瘤个体化用药指导靶基因检测”临床技术服务,同时为临床提供疾病早期筛查、重大疾病分子标志物检测及与保健、优生优育相关的检测服务。与国内顶级医院及科研机构携手,开拓高通量基因测序技术在生命科学与医疗健康领域中的广阔应用,为人类的健康事业提供专业、贴心的个性化服务。

华因康基因(集团)将始终坚持“探索基因信息,提高生命价值”的宗旨,致力于打造基因生命科技在研发、应用、临床转化系统平台技术上的核心竞争力,彰显中国基因产业在世界竞争中的领航者地位,引领中国健康产业发展新方向。


Huayinkang group adheres to the concept of "professional, rigorous, innovative and service". Since its establishment in 2008, it has been committed to the cause of health of the Chinese nation, with rapid development. So far, it has Shenzhen huayinkang high throughput Biotechnology Research Institute, Shenzhen huayinkang Gene Technology Co., Ltd., huayinkang gene testing center and many branches all over the country. It has become a biotechnology high-tech group with gene technology as the core, strong R & D support, and a complete industrial chain of R & D, production and application. R & D Center - Shenzhen huayinkang high throughput Biotechnology Research Institute has an elite technical team composed of scientists, professors, doctors, postdoctors and industry experts with cutting-edge technical achievements in the fields of machinery, optics, electronics, biochemistry, software, biological information, biomedicine and other technical fields. Facing the needs of the world's scientific frontier and national strategic development, and taking the breakthrough of new DNA sequencing analysis technology as an opportunity, the research institute aims to study high-throughput biotechnology, develop high-throughput experiment and detection equipment, find new high-throughput detection methods, make industrial layout for the upstream of China's life science and technology field, and build a basic research platform of life science and technology industry related to gene technology To carry out basic and applied research and technological development of international frontier genomic science and improve the independent innovation ability of China's gene technology. Product Center - Shenzhen huayinkang Gene Technology Co., Ltd. specializes in the production and sales of high-throughput gene sequencing equipment, biological reagents and gene information analysis software, providing scientific research and technical services and biological information data analysis technical services. The company's leading product, pstar high-throughput gene sequencing system, has filled in the gaps in the core equipment of life science and technology industry, gene sequencing equipment manufacturing, reagent production and bio information analysis services in China, and is widely used in basic research of life science, clinical diagnosis and treatment, disease prevention and health care, and new drug development and other fields. Based on the platform technology of new generation high-throughput gene sequencing system of huayinkang gene, huayinkang gene testing center is a professional transformation medicine service organization. The center takes the new generation high-throughput gene sequencing system technology platform as the core, supplemented by real-time fluorescent PCR platform, STR analysis platform, immunohistochemistry, fluorescence in situ hybridization and other technology platforms, covering DNA, RNA, protein level, sequencing, PCR, protein immunohistochemistry, fish and other detection technologies. It has taken the lead in developing a variety of clinical gene detection projects suitable for Asians, providing professional clinical technical services of "tumor individualized drug use guidance target gene detection", and providing early disease screening, detection of major disease molecular markers and detection services related to health care, eugenics and eugenics. Together with the top domestic hospitals and scientific research institutions, we will explore the wide application of high-throughput gene sequencing technology in the field of life science and medical health, and provide professional and intimate personalized services for human health. Huayinkang gene (Group) will always adhere to the tenet of "exploring gene information and improving life value", devote itself to building the core competitiveness of gene life technology in research and development, application and clinical transformation system platform technology, highlight the leading position of China's gene industry in the world competition, and lead the new development direction of China's health industry.

本文链接: https://brand.waitui.com/4c1ad289a.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

哈尔滨市19日启动“国补”家装消费品焕新活动

哈尔滨市将于5月19日正式启动“国补2025年家装消费品(家装建材领域)焕新活动”。本次活动补贴覆盖装修材料、卫生洁具、家具照明三大品类53小类产品。消费者购买符合条件产品,按剔除折扣后最终售价的15%享受立减补贴;购买1级能效或水效标准商品,补贴比例提升至20%。每位消费者每类产品限补贴1笔,单笔补贴不超过2000元,活动期间累计最高补贴15000元。(21财经)

4分钟前

中信证券:市场对于公募考核新规以及回归基准行业配置的讨论存在一些误区

36氪获悉,中信证券研报认为,市场对于公募考核新规以及回归基准行业配置的讨论存在一些误区。从海外经验来看,回归基准是通过基准的行业配比向基金持仓配比演化而不是相反;产品投资策略向客户盈利导向回归,在长期视野下,这与追求排名和绝对收益并不矛盾,反而是统一的;跑输基准的惩罚机制最终导致的是基金减少博弈性持仓,长期来看最大的影响是活跃头寸的占比下降。

4分钟前

如何把握并购重组的投资机遇?中金:重点关注四个方面

36氪获悉,中金公司研究部首席国内策略分析师李求索表示,重点关注四个方面的投资方向。一是科创龙头做优做强,本轮并购重组政策将对科技创新企业进一步加大支持力度。二是传统板块的产业整合趋势,结合历史数据,行业集中度偏低的领域,企业并购重组意愿相对较强。三是新形势下国央企市值管理意愿有望提升,并购重组作为市值管理的重要方向之一,从国央企的角度边际意愿有望增加。四是未上市企业的多元选择,近年在IPO环境变化背景下,不少未上市公司也选择并购重组作为公司方向性考量。

4分钟前

河北医保基金即时结算超20亿元

据国家医保局消息,医保基金是群众看病就医的“保命钱”,也是医疗服务和医药产品的重要资金来源,即时结算是今年医保改革的重要举措。河北省省市县(区)医保部门全面开展即时结算改革工作,定点医药机构医保费用日日有回款。截至5月8日,累计向18413家定点医药机构拨付医保基金20.17亿元。(21财经)

4分钟前

天问二号探测器顺利转入发射区,计划5月底择机发射

来自国家航天局的消息,5月18日,行星探测工程天问二号探测器在西昌卫星发射中心按计划完成技术区总装、测试、加注等工作后,顺利转入发射区,后续将按计划开展各项功能检查、联合测试等工作,计划5月底择机实施发射。天问二号任务将通过一次发射,实施小行星2016HO3伴飞、取样、返回和主带彗星311P伴飞探测等多项任务。(央视新闻)

4分钟前

本页详细列出关于HYK华因康的品牌信息,含品牌所属公司介绍,HYK华因康所处行业的品牌地位及优势。
咨询